UBS Group AG Sells 33,441 Shares of HealthEquity, Inc. (NASDAQ:HQY)

UBS Group AG lessened its holdings in HealthEquity, Inc. (NASDAQ:HQY – Get Rating) by 50.6% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 32,592 shares of the company’s stock after selling 33,441 shares during the period. UBS Group AG’s holdings in HealthEquity were worth $2,189,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the business. BlackRock Inc. lifted its stake in shares of HealthEquity by 4.0% in the 1st quarter. BlackRock Inc. now owns 9,423,008 shares of the company’s stock worth $635,488,000 after purchasing an additional 358,743 shares during the period. Wasatch Advisors Inc. lifted its stake in shares of HealthEquity by 3.3% in the 1st quarter. Wasatch Advisors Inc. now owns 7,638,935 shares of the company’s stock worth $515,170,000 after purchasing an additional 244,868 shares during the period. FMR LLC lifted its stake in shares of HealthEquity by 11.6% in the 2nd quarter. FMR LLC now owns 3,589,800 shares of the company’s stock worth $220,378,000 after purchasing an additional 373,264 shares during the period. State Street Corp lifted its stake in shares of HealthEquity by 2.6% in the 1st quarter. State Street Corp now owns 2,642,658 shares of the company’s stock worth $178,221,000 after purchasing an additional 68,071 shares during the period. Finally, Kayne Anderson Rudnick Investment Management LLC lifted its stake in shares of HealthEquity by 2.2% in the 2nd quarter. Kayne Anderson Rudnick Investment Management LLC now owns 1,410,226 shares of the company’s stock worth $86,574,000 after purchasing an additional 30,886 shares during the period. Institutional investors own 99.54% of the company’s stock.

Insider Activity at HealthEquity

In related news, Director Gayle Furgurson Wellborn sold 5,237 shares of the firm’s stock in a transaction on Wednesday, December 14th. The shares were sold at an average price of $62.00, for a total value of $324,694.00. Following the completion of the transaction, the director now directly owns 12,023 shares of the company’s stock, valued at $745,426. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 2.80% of the stock is currently owned by insiders.

HealthEquity Trading Up 2.1 %

Shares of HQY opened at $67.41 on Wednesday. The company has a debt-to-equity ratio of 0.48, a current ratio of 3.01 and a quick ratio of 3.01. HealthEquity, Inc. has a 1 year low of $50.59 and a 1 year high of $79.20. The company has a 50 day simple moving average of $61.70 and a two-hundred day simple moving average of $65.37. The firm has a market cap of $5.71 billion, a P/E ratio of -96.30, a price-to-earnings-growth ratio of 2.28 and a beta of 0.80.

HealthEquity (NASDAQ:HQY – Get Rating) last posted its earnings results on Tuesday, December 6th. The company reported $0.21 earnings per share for the quarter, beating analysts’ consensus estimates of $0.20 by $0.01. HealthEquity had a negative net margin of 7.07% and a positive return on equity of 2.82%. The firm had revenue of $216.09 million during the quarter, compared to analyst estimates of $206.58 million. On average, equities analysts expect that HealthEquity, Inc. will post 0.75 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on HQY shares. Raymond James increased their target price on shares of HealthEquity from $75.00 to $85.00 and gave the stock an “outperform” rating in a report on Monday, December 12th. Wells Fargo & Company reduced their target price on shares of HealthEquity from $101.00 to $89.00 and set an “overweight” rating for the company in a report on Friday, February 3rd. Royal Bank of Canada increased their target price on shares of HealthEquity from $70.00 to $75.00 in a report on Monday, December 5th. Robert W. Baird increased their target price on shares of HealthEquity to $75.00 in a report on Monday, December 12th. Finally, Deutsche Bank Aktiengesellschaft increased their target price on shares of HealthEquity from $68.00 to $72.00 and gave the stock a “buy” rating in a report on Tuesday, January 24th. Three equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, HealthEquity has a consensus rating of “Moderate Buy” and an average price target of $80.62.

HealthEquity Profile

(Get Rating)

HealthEquity, Inc provides range of solutions for managing health care accounts. The firm’s offers its solutions for employers, health plans, brokers, consultants and financial advisors. Its services include HAS, FSA, HRA, DCRA, 401(k), Commuter, COBRA and HIA. It also offers products like healthcare saving and spending platform, health savings accounts, investment advisory services, reimbursement arrangements, and healthcare incentives.